Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.0850 (2.21%) ($5.0850 - $5.0850) on Thu. May. 26, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.33% (three month average) | RSI | 31 | Latest Price | $5.0850(2.21%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -3.4% a day on average for past five trading days. | Weekly Trend | TGTX declines -9.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(75%) ARKG(70%) IBB(65%) ARKK(62%) IBUY(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.165% in a week (0% probabilities). VIXM(-52%) VXX(-39%) UUP(-20%) TBT(-16%) USO(-9%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.165% (StdDev 6.33%) | Hourly BBV | 0.9 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-19.12(-476.01%) | Resistance Level | $6.28 | 5 Day Moving Average | $5.16(-1.45%) | 10 Day Moving Average | $5.73(-11.26%) | 20 Day Moving Average | $6.28(-19.03%) | To recent high | -51.8% | To recent low | 3.7% | Market Cap | $644m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |